Stephen Ranere is a partner in the Boston office of Latham & Watkins and a member of the firm's Emerging Companies Practice. He represents emerging companies and venture capital firms involved in the technology and life sciences industries. His practice focuses on: general corporate counseling, early stage company formation and strategy, initial through late stage venture capital financings, mergers and acquisitions, and public securities offerings.
Mr. Ranere was a member of the Suffolk University Law Review and was awarded the Daniel J. Fern Award for highest grade point average.
Prior to law school, Mr. Ranere held business development positions with Sophos, a provider of network anti-virus solutions, and CipherTrust (later acquired by McAfee), a provider of email and internet security products.
Mr. Ranere frequently lends his time and legal advice to local community organizations, including TiE Boston, a nonprofit association dedicated to fostering entrepreneurship, and More Than Words, a nonprofit social enterprise empowering high-risk young adults to take charge of their lives.
Mr. Ranere’s representative transactions include:
- Neurogene on its US$115 million equity financing and numerous other private financings
- Kiniksa Pharmaceuticals on its US$150 million IPO and multiple private financings and strategic transactions
- Rapid Micro Biosystems on a US$60 million equity financing led by Bain Capital Life Sciences and numerous other private financings
- CloudHealth on its sale to VMware, Inc. (terms undisclosed)
- Juventas Therapeutics in multiple private financings
- Actifio on its sale to Google and numerous debt and equity financings
- Charles River Systems on its US$2.6 billion sale to State Street Corporation
- Amphenol on its US$400 million acquisition of SSI Controls Technologies
- Veracode on its US$614 million sale to CA Technologies
- Care.com in its IPO and numerous acquisitions
- Zipcar on its IPO and sale to Avis Budget Group
- SpaceClaim on its sale to ANSYS
- The Echo Nest on its sale to Spotify (terms undisclosed)